Navigation Links
Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress

Nasalfent shows clinically meaningful pain relief within 5 minutes of dosing and is well-tolerated

READING, England, 7 June 2007 - Archimedes Pharma Ltd ("Archimedes"), a European specialty pharmaceutical company, today presented new clinical data from a Phase II study of Nasalfent(r), an innovative fentanyl citrate nasal spray aimed at providing a fast, effective and convenient treatment for breakthrough cancer pain. Data were presented at the 10th Congress of the European Association for Palliative Care (EAPC) in Budapest showing that Nasalfent can give significant, clinically meaningful levels of pain relief and a reduction in pain intensity within 5 minutes of dosing.

The open-label, multi-centre study, was conducted in two parts - the first to establish an effective dose for each patient, followed by an efficacy phase in which the dose identified in part one was evaluated using a series of measures for pain relief. Statistically significant improvements from baseline in pain intensity and onset of pain relief were seen within five minutes of dosing (both p<0.05) in the 15 patients included in the efficacy analysis. All patients experienced at least one episode with meaningful pain relief and in the 55 breakthrough cancer pain episodes assessed, some degree of pain relief was recorded in 96% and clinically meaningful pain relief in 73%.

All doses of Nasalfent from 25mcg to 800mcg were well-tolerated, with no significant nasal findings or symptoms of irritation seen at any dose. In a patient satisfaction survey, 77% rated the product as 'good', 'very good' or 'excellent'.

Principal Investigator Dr Geoff Davis, Medical Director of Palliative Care, St Joseph's Care Group, Thunder Bay, Ontario, Canada said: "Breakthrough cancer pain is a significant clinical problem which requires a drug with a fast and reliable onset of action, together with ease of use and high patient acceptabilit
'"/>




Page: 1 2 3

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... DUBAI, UAE, February 8, 2012 In the ... diabetic; six countries in the MENA region are among the ... include the United Arab Emirates, Bahrain, Egypt, Kuwait, Oman and ... accounting for 14 percent of its total health care expenditure ...
... 7, 2012  Prometheus Laboratories Inc., a specialty pharmaceutical ... a research and collaboration agreement with an unnamed ... Prometheus, proprietary oncology diagnostic platform (CEER) to develop ... The CEER arrays may ultimately be used in ...
Cached Medicine Technology:Meeting of the Region's Top Diabetes Experts in Dubai this March 2Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company 2
(Date:1/22/2015)... 22, 2015 Woodloch Pines, an all-inclusive ... selected by TripAdvisor as the number one best large hotel ... in the world for their annual Travelers’ Choice Awards. ... . The website is home to millions of unbiased and ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... back to the cancer communities in the cities visited ... Society for Therapeutic Radiology and Oncology (ASTRO) is partnering ... of cancer survivorship. The Kenneth B. Schwartz Center conducts ... the art of compassionate healthcare. , The Kenneth B. ...
... instances of Salmonella poisoning linked to a jalapeno pepper in Texas, ... sweating it out over the jalapeno crisis do not have to ... Resource reveals some fiery competition. , ... LENEXA, ...
... of articles and magazine covers talk about retirement, but the fact is ... By 2010, 58 million people--20% of the population--will be 50-64. ... survive and thrive in this challenging PreRetirement life stage? , ... (PRWEB) ...
... of Public Health Confirms Positive Review ... of DNA ... it received a formal letter from the California Department of Public,Health (CDPH) ... letter states that DNA Direct,s tests are,performed only with a physician order ...
... Inc. (Amex: ADK ), an Ohio based long ... refinancing of one of its nursing,homes in Ohio., ... single story nursing home,facility located in Greenfield, Ohio. Recently, ... of the art private bedrooms, along with a new,kitchen, ...
... Foundation to Provide Health Coverage Eligibility Screening and ... Application Assistance to Uninsured, ... wholly funded by WellPoint, Inc., has,awarded The CoverMe Foundation a ... in identifying and assisting uninsured persons,and families in finding and ...
Cached Medicine News:Health News: No More Jalapenos? No Problemo! Salmonella-Free Alternatives : No More Jalapenos? No Problemo, yes Poblano! 2Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 2Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 3Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 4Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 5Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 6Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 7Health News:DNA Direct Confirms It Is Operating in Compliance with California State Laboratory Law 2Health News:AdCare Health Systems, Inc. Announces the Refinancing of a Nursing Home in Ohio 2Health News:WellPoint Foundation Awards $2.5 Million Grant to The CoverMe Foundation 2Health News:WellPoint Foundation Awards $2.5 Million Grant to The CoverMe Foundation 3
... of the outstanding features of our Neomax ... Molding Technology. , This manufacturing process allows ... controls the bunching and irritation in the ... wearer. , ,Colors available: Blue, ...
... Flex™ might just be the world's most ... functional support, post-op/rehab support, or both, Flex ... new Accutrac™ ROM hinges control flexion and ... long-term durability while being heat-moldable to accommodate ...
... Donut is a neoprene alternative, constructed ... polyester Lycra Fabric that allows for ... provides for patellar control. Ideal for ... or irritations. Click here to view ...
... of the TROM provides the same easy ... as the full foam TROM, but is ... of use and versatility of the Cool ... following major ligament surgery, meniscal repairs, patella ...
Medicine Products: